跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Selective Killing: How Chemotherapy Harms Cancer Cells More Than Normal Cells

1The Selectivity Problem: Why Preferential Killing Is Possible but Imperfect2Proliferation as the Primary Vulnerability: Cell-Cycle Dependence3Antimetabolites and the S-Phase Trap4Microtubule Poisons and Mitotic Arrest5DNA-Damaging Agents: Alkylators, Crosslinkers, and Topoisomerase Poisons6The DNA-Damage Response and the Decision to Die7Why Selectivity Fails: Normal-Tissue Toxicity and the Limits of the Window8Resistance: How Tumors Escape and What It Reveals About Selectivity9Widening the Window: Clinical Strategies That Exploit Selectivity
Widening the Window: Clinical Strategies That Exploit Selectivity

Stacking Mechanisms and Timing Doses to Widen the Gap

1 / 3
The regimen example is worth walking through slowly, because it shows that selectivity is engineered, not just discovered. The alkylator damages DNA; the microtubule poison disrupts mitosis. A tumor cell that has amplified its efflux pumps handles the alkylator but still walks into the microtubule poison, and a cell with upregulated DNA repair handles the alkylator's lesions but has no defense against a spindle it cannot assemble. That is the resistance argument. The toxicity argument runs in parallel: the alkylator's ceiling is set by bone marrow, the microtubule poison's ceiling by nerve tissue. Because those ceilings sit on different organs, each drug can be pushed near its own limit. Had both been myelosuppressive, the shared ceiling would have forced both doses down, and the tumor would have gained ground.
0:00 / 0:00

Two independent reasons to combine

Combination therapy widens the window for two separate reasons. Mechanistically, requiring a cell to defeat two unrelated killing mechanisms at once makes the resistant phenotype rare. Toxicologically, choosing agents whose dose-limiting toxicities fall on different normal tissues lets each drug be given near its own maximum tolerated dose instead of forcing a shared reduction.

The design rule

A rational combination pairs agents with non-overlapping mechanisms of action and non-overlapping dose-limiting toxicities. Overlap in either dimension narrows the window instead of widening it.

Why timing is a selectivity tool

Normal proliferating tissues recover faster than tumor tissue between cytotoxic insults, so the normal-tissue dose-response curve returns toward baseline while the tumor curve does not. Dose-dense scheduling shortens the interval to exploit that difference. For phase-specific agents, which kill only cells in a particular cell-cycle phase, prolonged or repeated exposure is required so that a larger fraction of the tumor passes through the vulnerable phase while the drug is present.

Reading a regimen as a window argument

Consider a regimen combining a DNA-damaging alkylator with a microtubule poison. The two agents act at different points in the drug-to-death chain, so a cell that effluxes the alkylator well is not automatically protected against the microtubule poison, and a cell with enhanced DNA repair is not protected against mitotic disruption. Their dose-limiting toxicities also differ: the alkylator is limited mainly by bone-marrow suppression, while the microtubule poison is limited by peripheral neuropathy. Because the two normal-tissue curves peak on different tissues, each drug can be pushed close to its own ceiling. If instead both agents were myelosuppressive, the shared ceiling would force dose reduction of both, and the tumor curve would move right while the normal-tissue curve stayed put.

上一页1 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion